Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 376

The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors

Open access
Milbury, Coren A., Creeden, James, Yip, Wai-Ki, Smith, David L., Pattani, Varun, Maxwell, Kristi, Sawchyn, Bethany, Gjoerup, Ole, Meng, Wei, Skoletsky, Joel, Concepcion, Alvin D., Tang, Yanhua, Bai, Xiaobo, Dewal, Ninad, Ma, Pei, Bailey, Shannon T., Thornton, James, Pavlick, Dean C., Frampton, Garrett M., Lieber, Daniel, White, Jared, Burns, Christine, Vietz, Christine·2022·PLOS ONE

Abstract

FoundationOne®CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-approved companion diagnostic test to identify patients who may benefit from treatment in accordance with the approved therapeutic product labeling for 28 drug therapies. F1CDx utilizes next-generation sequencing (NGS)-based comprehensive genomic profiling (CGP) technology to examine 324 cancer genes in solid tumors. F1CDx reports known and likely pathogenic short variants (SVs), copy number alterations (CNAs), and select rearrangements, as well as complex biomarkers including tumor mutational burden (TMB) and microsatellite instability (MSI), in addition to genomic loss of heterozygosity (gLOH) in ovarian cancer. CGP services can reduce the complexity of biomarker testing, enabling precision medicine to improve treatment decision-making and outcomes for cancer patients, but only if test results are reliable, accurate, and validated clinically and analytically to the highest standard available. The analyses presented herein demonstrate the extensive analytical and clinical validation supporting the F1CDx initial and subsequent FDA approvals to ensure high sensitivity, specificity, and reliability of the data reported. The analytical validation included several in-depth evaluations of F1CDx assay performance including limit of detection (LoD), limit of blank (LoB), precision, and orthogonal concordance for SVs (including base substitutions [SUBs] and insertions/deletions [INDELs]), CNAs (including amplifications and homozygous deletions), genomic rearrangements, and select complex biomarkers. The assay validation of >30,000 test results comprises a considerable and increasing body of evidence that supports the clinical utility of F1CDx to match patients with solid tumors to targeted therapies or immunotherapies based on their tumor’s genomic alterations and biomarkers. F1CDx meets the clinical needs of providers and patients to receive guideline-based biomarker testing, helping them keep pace with a rapidly evolving field of medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0264138

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 115 references

Cited by

See all 376

Metadata

Authors
Milbury, C. A., Creeden, J., Yip, W.-K., Smith, D. L., Pattani, V., Maxwell, K., Sawchyn, B., Gjoerup, O., Meng, W., Skoletsky, J., Concepcion, A. D., Tang, Y., Bai, X., Dewal, N., Ma, P., Bailey, S. T., Thornton, J., Pavlick, D. C., Frampton, G. M., Lieber, D., White, J., Burns, C., & Vietz, C.
Venue
PLOS ONE
Published
2022-03-16
Volume
17
Issue
3
Pages
e0264138
ISSN
1932-6203 (ISSN-L)
OpenAlex
W4220859775
Cited by
376
References
115
FWCI
24.44
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. https://app.cochat.ai/papers/10.1371/journal.pone.0264138
The paper
Milbury, C. A., Creeden, J., Yip, W.-K., Smith, D. L., Pattani, V., Maxwell, K., Sawchyn, B., Gjoerup, O., Meng, W., Skoletsky, J., Concepcion, A. D., Tang, Y., Bai, X., Dewal, N., Ma, P., Bailey, S. T., Thornton, J., Pavlick, D. C., Frampton, G. M., . . . Vietz, C. (2022). Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. PLOS ONE. https://doi.org/10.1371/journal.pone.0264138

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.